<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PREDNISTAB- prednisolone tablet </strong><br>Clipper Distributing Company LLC<br></p></div>
<h1>PrednisTab<span class="Sup">®</span><br> (Prednisolone, USP)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First">For Oral Use in Dogs Only</p>
</div>
<div class="Section" data-sectionCode="50741-8">
<a name="section-2"></a><p></p>
<h1>CAUTION</h1>
<p class="First">Federal law restricts this drug to use by or on the order of a licensed veterinarian.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-3"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Prednisolone, like methylprednisolone, is a potent anti-inflammatory steroid. Prednisolone, 11,17,21-trihydroxypregna-1,4-diene-3,20-dione, is a synthetic dehydrogenated analogue of cortisone. Prednisolone and methylprednisolone have a greater anti-inflammatory potency and less tendency to induce sodium and <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">water retention</span> than the older corticoids, cortisone and hydrocortisone. The relative anti-inflammatory potency for hydrocortisone is 1.0; cortisone is 0.8; prednisolone is 4 and methylprednisolone is 5. The relative sodium retaining potency for hydrocortisone is 4; prednisolone is 3 and methylprednisolone is 2.<span class="Sup">1,2</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS</h1>
<p class="First">PrednisTab is intended for use in dogs. The indications for PrednisTab are the same as those for other anti-inflammatory steroids and comprise the various collagen, dermal, allergic, ocular, otic, and musculoskeletal conditions known to be responsive to the anti-inflammatory corticosteroids. Representative of the conditions in which the use of steroid therapy and the benefits to be derived therefrom have had repeated confirmation in the veterinary literature are: (1) dermal conditions, such as nonspecific <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span>, summer <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, and <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">burns</span>; (2) allergic manifestations, such as <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">acute urticaria</span>, <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">allergic dermatitis</span>, drug and serum reactions, bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, and pollen sensitivities; (3) ocular conditions, such as <span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">iritis</span>, <span class="product-label-link" type="condition" conceptid="434926" conceptname="Iridocyclitis">iridocyclitis</span>, secondary <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, <span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">uveitis</span>, and <span class="product-label-link" type="condition" conceptid="434033" conceptname="Chorioretinitis">chorioretinitis</span>; (4) otic conditions, such as <span class="product-label-link" type="condition" conceptid="380731" conceptname="Otitis externa">otitis externa</span>; (5) musculoskeletal conditions, such as <span class="product-label-link" type="condition" conceptid="73001" conceptname="Myositis">myositis</span>, <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>, <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span>, and <span class="product-label-link" type="condition" conceptid="134453" conceptname="Bursitis">bursitis</span>; (6) various chronic or recurrent diseases of unknown etiology such as <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> and <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrosis</span>.</p>
<p>In acute <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span>, prednisolone may be effective because of its ability to correct the defect in carbohydrate metabolism and relieve the impaired diuretic response to water, characteristic of primary or <span class="product-label-link" type="condition" conceptid="4042063" conceptname="Hypocortisolism secondary to another disorder">secondary adrenal insufficiency</span>. However, because this agent lacks significant mineralocorticoid activity, hydrocortisone sodium succinate, hydrocortisone, or cortisone should be used when <span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">salt retention</span> is indicated.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Do not use in <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span>. Prednisolone, like methylprednisolone, is contraindicated in animals with <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span>, <span class="product-label-link" type="condition" conceptid="373202" conceptname="Corneal ulcer">corneal ulcer</span>, and <span class="product-label-link" type="condition" conceptid="4195232" conceptname="Cushingoid facies">Cushingoid</span> syndrome. The presence of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>, predisposition to <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, and active <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> necessitates carefully controlled use. Some of the above conditions occur only rarely in dogs but should be kept in mind.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6"></a><p></p>
<h1>CAUTION</h1>
<p class="First">Because of its inhibitory effect on fibroplasia, prednisolone may mask the signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and enhance dissemination of the infecting organism. Hence, all animal patients receiving prednisolone should be watched for evidence of intercurrent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Should <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> occur, it must be brought under control by use of appropriate antibacterial measures, or administration of prednisolone should be discontinued.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-7"></a><p></p>
<h1>Warning</h1>
<p class="First">Not for human use. Clinical and experimental data have demonstrated that corticosteroids administered orally or by injection to animals may induce the first stage of parturition if used during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal death</span>, <span class="product-label-link" type="condition" conceptid="4003030" conceptname="Retained placenta">retained placenta</span>, and metritis.</p>
<p>Additionally, corticosteroids administered to dogs, rabbits, and rodents during pregnancy have resulted in <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span> in offspring. Corticosteroids administered to dogs during pregnancy have also resulted in other congenital anomalies, including deformed forelegs, <span class="product-label-link" type="condition" conceptid="73307" conceptname="Transverse deficiency of lower limb">phocomelia</span>, and <span class="product-label-link" type="condition" conceptid="4043107" conceptname="Anasarca">anasarca</span>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-8"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First">Prednisolone, like methylprednisolone and other adrenocortical steroids, is a potent therapeutic agent influencing the biochemical behavior of most, if not all, tissues of the body. Because this anti-inflammatory steroid manifests little sodium-retaining activity, the usual early sign of cortisone or hydrocortisone overdosage (i.e., increase in body weight due to <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>) is not a reliable index of overdosage. Hence, recommended dose levels should not be exceeded, and all animal patients receiving prednisolone should be under close medical supervision. All precautions pertinent to the use of methylprednisolone apply to prednisolone. Moreover, the veterinarian should endeavor to keep informed of current studies of corticosteroids as they are reported in the veterinary literature.</p>
<p>Use of corticosteroids, depending on dose, duration and specific steroid, may result in inhibition of endogenous steroid production following drug withdrawal. In patients presently receiving or recently withdrawn from systemic corticosteroid treatments, therapy with a rapid-acting corticosteroid should be considered in unusually stressful situations.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-9"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Prednisolone is similar to methylprednisolone in regard to kinds of side effects and metabolic alterations to be anticipated when treatment is intensive or prolonged. In animal patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, use of prednisolone may be associated with an increase in the insulin requirement. Negative nitrogen balance may occur, particularly in animals that require protracted maintenance therapy; measures to counteract persistent nitrogen loss include a high protein intake and the administration, when indicated, of a suitable anabolic agent. Excessive loss of potassium, like excessive retention of sodium, is not likely to be induced by effective maintenance doses of prednisolone. However, these effects should be kept in mind and the usual regulatory measures employed as indicated. Ecchymotic manifestations in dogs may occur. If such reactions do occur and are serious, reduction in dose or discontinuance of prednisolone therapy may be indicated.</p>
<p>Side effects, such as SAP and SALT enzyme elevations, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="432454" conceptname="Excessive thirst">polydipsia</span> and <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span> have occurred following the use of synthetic cortico-steroids in dogs. <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (occasionally bloody) have also been observed. Cushing's syndrome in dogs has been reported in association with prolonged or repeated steroid therapy.</p>
<p>Since prednisolone, like methylprednisolone, suppresses endogenous adrenocortical activity,<span class="Italics"> it is highly important that the animal patient receiving prednisolone be under careful observation, not only during the course of treatment but for some time after treatment is terminated. Adequate adrenocortical supportive therapy with cortisone or hydrocortisone, and including ACTH, must be employed promptly if the animal is subjected to any unusual stress such as surgery, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, or severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</span></p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-10"></a><p></p>
<h1>ADMINISTRATION</h1>
<p class="First">The keystone of satisfactory therapeutic management with PrednisTab prednisolone tablets, as with other steroid predecessors, is individualization of dosage in reference to the severity of the disease, the anticipated duration of steroid therapy, and the animal patient's threshold or tolerance for steroid excess. The prime objective of steroid therapy should be to achieve a satisfactory degree of control with a minimum effective daily dose.</p>
<p>The dosage recommendations are suggested<span class="Bold"> average total daily doses </span><span class="Italics">and are intended as guides</span>. As with other orally administered corticosteroids, the total daily dose of prednisolone should be given in equally divided doses. The initial suppressive dose level is continued until a satisfactory clinical response is obtained, a period usually of 2 to 7 days in the case of musculoskeletal diseases, allergic conditions affecting the skin or respiratory tract, and ocular inflammatory diseases. If a satisfactory response is not obtained in 7 days, reevaluation of the case to confirm the original diagnosis should be made. As soon as a satisfactory clinical response is obtained, the daily dose should be reduced gradually, either to termination of treatment in the case of acute conditions (e.g., seasonal <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, acute ocular <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammations</span>) or to the minimal effective maintenance dose level in the case of chronic conditions (e.g., <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>). In chronic conditions, and in <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> especially, it is important that the reduction in dosage from initial to maintenance dose levels be accomplished slowly. The maintenance dose level should be adjusted from time to time as required by fluctuation in the activity of the disease and the animal's general status. Accumulated experience has shown that the long-term benefits to be gained from continued steroid maintenance are probably greater the lower the maintenance dose level. In <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> in particular, maintenance steroid therapy should be at the lowest possible level.</p>
<p><span class="Bold">Important: </span>In the therapeutic management of animal patients with chronic diseases such as <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>, prednisolone should be regarded as a highly valuable adjunct, to be used in conjunction with, but<span class="Italics"> not as replacement </span>for, standard therapeutic measures.</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="section-11"></a><p></p>
<h1>DOSAGE</h1>
<p class="First"><span class="Italics">2.5 mg per 10 lb (4.5 kg) body weight per day. Average total daily oral doses for dogs as follows:</span></p>
<table width="60%">
<col align="left" valign="top" width="75%">
<col align="right" valign="top" width="25%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="left">5 to 20 lb (2 to 9 kg) body weight</td>
<td align="right">1.25 to 5 mg</td>
</tr>
<tr>
<td align="left">20 to 40 lb (9 to 18 kg) body weight</td>
<td align="right">5 to 10 mg</td>
</tr>
<tr>
<td align="left">40 to 80 lb (18 to 36 kg) body weight</td>
<td align="right">10 to 20 mg</td>
</tr>
<tr class="Botrule Last">
<td align="left">80 to 160 lb (36 to 73 kg) body weight</td>
<td align="right">20 to 40 mg</td>
</tr>
</tbody>
</table>
<p>The total daily dose should be given in divided doses, 6 to 10 hours apart.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">PrednisTab is available as 5 mg compressed quarter-scored tablets in bottles of 1000 and 20 mg compressed quarter-scored tablets in bottles of 500.</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-12.1"></a><p></p>
<h2>STORAGE</h2>
<p class="First">Store at controlled room temperature 15°- 30° C (59° - 86° F).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13"></a><p></p>
<p class="First"><span class="Bold">Manufactured by<br>LLOYD, Inc.<br>Shenandoah, Iowa 51601 U.S.A.</span></p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-14"></a><p></p>
<h1>References</h1>
<ol class="Arabic">
<li>Liddle, G.W. 1958. Studies of structure-function relationship of steroids. II. The 6α− methylcorticosteroids. Metab. Clin. Exp. 7:405-415.</li>
<li>Haynes, R.C., Jr. 1990. Adrenocorticotropic hor- mone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. Pages 1431-1462 <span class="Underline">in</span> A.G. Gilman et al, eds. <span class="Underline">The Pharmacologica Basis of Therapeutics.</span> 8th Ed., Pergamon Press, Elmsford, New York.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15"></a><p></p>
<p class="First">0111</p>
<p>NADA # 140-921, Approved by FDA</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-16"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 5 mg Tablet Bottle Label</h1>
<p class="First"><span class="Bold">NDC 57319-441-16</span></p>
<p><span class="Bold">PrednisTab<span class="Sup">®</span><br>(Prednisolone Tablets, USP)<br>5 mg </span></p>
<p><span class="Bold">For Oral Use in Dogs Only</span></p>
<p><span class="Bold">NADA# 140-921, Approved by FDA</span></p>
<p><span class="Bold">FOR ANIMAL USE ONLY</span></p>
<p><span class="Bold">KEEP OUT OF REACH<br>OF CHILDREN</span></p>
<p><span class="Bold">CAUTION: </span>Federal law<br>restricts this drug to use<br>by or on the order of a<br>licensed veterinarian.</p>
<p><span class="Bold">Net Contents:<br>1000 Tablets</span></p>
<p><span class="Bold">PHOENIX</span>™</p>
<p><span class="Bold">Manufactured for:<br>Clipper Distributing Company, LLC<br>St. Joseph, MO 64507</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 5 mg Tablet Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3404a338-db7f-4550-9d4c-33aa0782d01a&amp;name=prednis-01.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PREDNISTAB 		
					</strong><br><span class="contentTableReg">prednisolone tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PRESCRIPTION ANIMAL DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:57319-441</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PREDNISOLONE</strong> (PREDNISOLONE) </td>
<td class="formItem">PREDNISOLONE</td>
<td class="formItem">5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>.ALPHA.-TOCOPHEROL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS CITRIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BUTYLATED HYDROXYTOLUENE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">4 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">PT5</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:57319-441-16</td>
<td class="formItem">1000  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NADA</td>
<td class="formItem">NADA140921</td>
<td class="formItem">11/08/1991</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Clipper Distributing Company LLC
							(150711039)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>LLOYD, Inc. of Iowa (962286535)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">LLOYD, Inc. of Iowa</td>
<td class="formItem"></td>
<td class="formItem">962286535</td>
<td class="formItem">MANUFACTURE, LABEL, PACK</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">LLOYD, Inc. of Iowa</td>
<td class="formItem"></td>
<td class="formItem">007281942</td>
<td class="formItem">ANALYSIS</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Sanofi Chimie</td>
<td class="formItem"></td>
<td class="formItem">291538267</td>
<td class="formItem">API MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>a1d792cc-7939-414d-800f-b6d4f912ec34</div>
<div>Set id: 3404a338-db7f-4550-9d4c-33aa0782d01a</div>
<div>Version: 2</div>
<div>Effective Time: 20140828</div>
</div>
</div> <div class="DistributorName">Clipper Distributing Company LLC</div></p>
</body></html>
